Review



recombinant human ctla4 ig fc  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems recombinant human ctla4 ig fc
    Recombinant Human Ctla4 Ig Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Recombinant+Human+CTLA-4+Fc+Chimera+His-tag+Protein/us12569592-1762-0-3
    Average 94 stars, based on 7 article reviews
    recombinant human ctla4 ig fc - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Human CTLA-4 antibodies and their uses
    Article Snippet: .. Soluble Antigen Recombinant CTLA-4 fusion protein comprising the extracellular domain of human CTLA-4 was purchased from R&D Systems (Cat. #325-CT-200). ..

    Article Title: Transgenic trasnchromosomal rodents for making human antibodies
    Article Snippet: .. Soluble recombinant antigen comprising the extracellular domain of human CTLA-4 was purchased from R&D Systems (Cat #325-CT-200). ..

    Article Title: Immune checkpoint inhibitors and reproductive failures.
    Article Snippet: The human conceptus is a semi-allograft, which is antigenically foreign to the mother.. Hence, the implantation process needs mechanisms to prevent allograft rejection during successful pregnancy.. Immune checkpoints are a group of inhibitory pathways expressed on the surface of various immune cells in the form of ligand receptors.

    Article Title: Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.
    Article Snippet: Anti-CTLA4 biological activity and FACS array PBMCs or Jurkat cells were stimulated with 0.3mg ml 1l ionomycin (SigmaAldrich Co., St Louis, MO, USA), 0.03mg ml 1 phorbol myristate acetate (PMA) (Sigma-Aldrich Co.) and 1mg ml 1 recombinant human B7 Fc Chimera (R&D Systems, Abingdon, England, UK), and treated with 0.02-mm filtered (Whatman Anotop) supernatants of virus-infected PC3-MM2 cells. .. In the loss-of-function assay, 0.1mg ml 1 recombinant human CTLA-4/Fc chimera (R&D Systems) was added to ionomycin, PMA and recombinant B7. .. Twenty-four hours after PBMC stimulation or 48 h after Jurkat cell stimulation, the IL-2 or IFN-g levels in the growth media were analyzed by using the BD Cytometric Bead Array Human Soluble Protein Flex Set (Becton Dickinson, Helsinki, Finland) according to the manufacturer’s instructions.

    Article Title: XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
    Article Snippet: The diluted XTX100- Fab was then immobilized to a CM5 sensor chip via amine coupling (BR100050, Cytiva). .. Peptides were flowed over the chip at concentrations of 1–100 μM at a temperature of 37°C. mAb binding to hCTLA-4 Recombinant human CTLA- 4- Fc (7268- CT- 100, R&D Systems) was diluted to 30 μg/mL in 50 mM sodium acetate pH 5.0. .. The diluted antigen was then immobilized onto a carboxymethyl dextran- coated SPR sensor chip (13206066, Reichert Technologies) via amine coupling (BR100050, Cytiva).

    Article Title: Human CTLA-4 antibodies and their uses
    Article Snippet: .. Soluble Antigen Recombinant CTLA-4 fusion protein comprising the extracellular domain of human CTLA-4 was purchased from R&D Systems (Cat. #325-CT-200). ..

    Article Title: Transgenic transchromosomal rodents for making human antibodies
    Article Snippet: .. Soluble recombinant antigen comprising the extracellular domain of human CTLA-4 was purchased from R&D Systems (Cat #325-CT-200). ..

    Article Title: Antibodies and nucleotide sequences, and uses thereof
    Article Snippet: .. As demonstrated in FIG. 6, the binding of CTLA-4 specific antibodies to human CTLA-4 expressing transfected cells can be inhibited by human and cynomologous recombinant protein (both R&D Systems). ..

    Expressing:

    Article Title: Immune checkpoint inhibitors and reproductive failures.
    Article Snippet: The human conceptus is a semi-allograft, which is antigenically foreign to the mother.. Hence, the implantation process needs mechanisms to prevent allograft rejection during successful pregnancy.. Immune checkpoints are a group of inhibitory pathways expressed on the surface of various immune cells in the form of ligand receptors.

    Article Title: Antibodies and nucleotide sequences, and uses thereof
    Article Snippet: .. As demonstrated in FIG. 6, the binding of CTLA-4 specific antibodies to human CTLA-4 expressing transfected cells can be inhibited by human and cynomologous recombinant protein (both R&D Systems). ..

    Binding Assay:

    Article Title: XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
    Article Snippet: The diluted XTX100- Fab was then immobilized to a CM5 sensor chip via amine coupling (BR100050, Cytiva). .. Peptides were flowed over the chip at concentrations of 1–100 μM at a temperature of 37°C. mAb binding to hCTLA-4 Recombinant human CTLA- 4- Fc (7268- CT- 100, R&D Systems) was diluted to 30 μg/mL in 50 mM sodium acetate pH 5.0. .. The diluted antigen was then immobilized onto a carboxymethyl dextran- coated SPR sensor chip (13206066, Reichert Technologies) via amine coupling (BR100050, Cytiva).

    Article Title: Antibodies and nucleotide sequences, and uses thereof
    Article Snippet: .. As demonstrated in FIG. 6, the binding of CTLA-4 specific antibodies to human CTLA-4 expressing transfected cells can be inhibited by human and cynomologous recombinant protein (both R&D Systems). ..

    Transfection:

    Article Title: Antibodies and nucleotide sequences, and uses thereof
    Article Snippet: .. As demonstrated in FIG. 6, the binding of CTLA-4 specific antibodies to human CTLA-4 expressing transfected cells can be inhibited by human and cynomologous recombinant protein (both R&D Systems). ..



    Similar Products

    94
    Sino Biological recombinant human ctla 4 protein
    Recombinant Human Ctla 4 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Human+CTLA4+Protein/pm41759845-77-12-18
    Average 94 stars, based on 1 article reviews
    recombinant human ctla 4 protein - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec ctla 4
    Ctla 4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/CD152+Antibody%2C+anti-human%2C+REAfinity/pm42455847-67-91-93
    Average 93 stars, based on 1 article reviews
    ctla 4 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec cd152 ctla 4 apc
    Cd152 Ctla 4 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/CD152+Antibody%2C+anti-human/pmc13053985-9-0-7
    Average 93 stars, based on 1 article reviews
    cd152 ctla 4 apc - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    86
    Agenus Inc humanized anti ctla 4 antibody hujs007 47
    Humanized Anti Ctla 4 Antibody Hujs007 47, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/anti+associated+cytotoxic+lymphocyte+t/us12655219-504-5-6
    Average 86 stars, based on 1 article reviews
    humanized anti ctla 4 antibody hujs007 47 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    93
    fluidigm anti human ctla 4 14d3 170er
    Effect of ADT + Fc-enhanced <t>anti-CTLA-4</t> on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.
    Anti Human Ctla 4 14d3 170er, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Anti-Human+CD152%2FCTLA-4+(14D3)-170Er/pmc13006393-95-0-5
    Average 93 stars, based on 1 article reviews
    anti human ctla 4 14d3 170er - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    fluidigm 3170005b
    Effect of ADT + Fc-enhanced <t>anti-CTLA-4</t> on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.
    3170005b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Anti-Human+CD152%2FCTLA-4+(14D3)-170Er/pmc13006393-95-9-5
    Average 93 stars, based on 1 article reviews
    3170005b - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant human ctla4 ig fc
    Effect of ADT + Fc-enhanced <t>anti-CTLA-4</t> on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.
    Recombinant Human Ctla4 Ig Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Recombinant+Human+CTLA-4+Fc+Chimera+His-tag+Protein/us12569592-1762-0-3
    Average 94 stars, based on 1 article reviews
    recombinant human ctla4 ig fc - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    Sino Biological human ctla 4 protein
    Effect of ADT + Fc-enhanced <t>anti-CTLA-4</t> on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.
    Human Ctla 4 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Human+CTLA4+Protein/us12564632-802-5-8
    Average 94 stars, based on 1 article reviews
    human ctla 4 protein - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    R&D Systems human ctla 4 fc fusion protein
    Effect of ADT + Fc-enhanced <t>anti-CTLA-4</t> on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.
    Human Ctla 4 Fc Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Recombinant+Human+CTLA-4+Fc+Chimera+His-tag+Protein/us12564632-778-2-7
    Average 94 stars, based on 1 article reviews
    human ctla 4 fc fusion protein - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    fluidigm 3161004b 171 yb foxp3
    Effect of ADT + Fc-enhanced <t>anti-CTLA-4</t> on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.
    3161004b 171 Yb Foxp3, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ctla/Anti-Human+CD152%2FCTLA-4+(14D3)-161Dy/pm41742894-272-42-40
    Average 93 stars, based on 1 article reviews
    3161004b 171 yb foxp3 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Effect of ADT + Fc-enhanced anti-CTLA-4 on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.

    Journal: Cell Reports Medicine

    Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial

    doi: 10.1016/j.xcrm.2026.102638

    Figure Lengend Snippet: Effect of ADT + Fc-enhanced anti-CTLA-4 on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.

    Article Snippet: Anti-Human CTLA-4 (14D3) 170Er , Standard BioTools , Cat# 3170005B.

    Techniques: Two Tailed Test, Biomarker Discovery, Expressing, Marker, Derivative Assay